Form 8-K
8-K — Entera Bio Ltd.
Accession: 0001178913-26-003946
Filed: 2026-08-07
Period: 2026-08-07
CIK: 0001638097
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Results of Operations and Financial Condition
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — zk2635891.htm (Primary)
EX-99.1 — EXHIBIT 99.1 (exhibit_99-1.htm)
GRAPHIC (image_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: zk2635891.htm · Sequence: 1
false
0001638097
00-0000000
0001638097
2026-05-08
2026-05-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 7, 2026
Entera Bio Ltd.
(Exact Name of Registrant as Specified in Its Charter)
Israel
001-38556
Not Applicable
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification)
Kiryat Hadassah, Minrav Building – Fifth
Floor, Jerusalem, Israel 9112002
(Address of principal executive offices) (Zip Code)
+972-2-532-7151
(Registrant’s Telephone Number, Including
Area Code)
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary Shares, par value of NIS 0.0000769
ENTX
Nasdaq Capital Market
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial
Condition.
On August 7, 2026, Entera Bio Ltd., a company
organized under the laws of the State of Israel (“we,” “us,” “our” or the “Company”),
issued a press release announcing its financial results for the three months ended June 30, 2026 and business updates. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.
Item 7.01 Regulation FD Disclosure.
The information contained in Item 2.02 of this
Current Report on Form 8-K is incorporated by reference in this Item 7.01.
The information contained in this Current Report
on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933,
as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
99.1
Press Release dated August 7, 2026 announcing the Company’s financial results for the three months
ended June 30, 2026 and business updates.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ENTERA BIO LTD.
Date: August 7, 2026
By:
/s/ Miranda Toledano
Name: Miranda Toledano
Title: Chief Executive Officer
EX-99.1 — EXHIBIT 99.1
EX-99.1
Filename: exhibit_99-1.htm · Sequence: 2
Exhibit 99.1
Entera Announces
Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment
on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women
with Osteoporosis
Oversubscribed $275 Million Private Placement
Led by BVF Partners L.P. (“BVF”) with Participation from Leading Institutional Healthcare Investors to Fund EB613 through
Anticipated Submission of NDA to the FDA
EB613 Phase 3 Study Initiation Planned for
Late 2026 with Topline Data Anticipated in the Second Half of 2028
IND Enabling Studies Ongoing for EB612 - the
First Oral Peptide Replacement Tablet in Development for Patients with Hypoparathyroidism – Intention to File IND in First Half
of 2027
TEL AVIV, August 7, 2026 -- Entera Bio Ltd. (NASDAQ:
ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today reported financial results
and key business updates for the quarter ended June 30, 2026.
“The first half of 2026 marked one of the
most consequential periods in Entera’s history. Since 2022, our core team embarked upon a journey of deconstruction and reconstruction
to advance our science and optimize our pipeline. Despite scarce resources and particularly turbulent times, today, our N-Tab®
platform is developing one of the richest pipelines of clinical and near-clinical first in class oral peptide assets; and we have
garnered the trust of global talent, luminaries, and financiers who support our mission and vision. Thank you. Osteoporosis is one of
the foremost underserved health issues globally, and associated fracture rates continue to rise despite existing treatments. Our discussions
with patients and their caregivers across primary care, gynecology, orthopedic surgery, rheumatology and endocrinology acknowledge the
urgent need for new treatments, especially, an oral anabolic therapy. We are developing EB613 to address this treatment gap. Our plan
is to do the same with EB612 for patients with hypoparathyroidism, also a women-centric condition. The capital raising transaction we
announced on July 27, 2026, led by BVF is transformational for Entera. To our knowledge, the transaction is the largest biotech PIPE and
the 9th largest PIPE, inclusive of the high-tech sector, on record in Israel. So, we shattered a few records and moving forward, we intend
to continue to shatter more records across all our programs with a cohesive, global team of colleagues who are obsessed with our vision
and steadfast in our execution,” said Miranda Toledano, Chief Executive Officer of Entera.
Key Recent Highlights
EB613: First Oral PTH(1-34) Anabolic Tablet
for Osteoporosis
· Positive FDA Feedback on 12-Month Registrational
Phase 3 Study Received: In June 2026, Entera announced that the FDA accepted Entera’s plan to conduct a single, randomized,
double-blind, placebo-controlled Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of
percent change from baseline in total hip bone mineral density (BMD) at Month 12 to support a potential new drug application (“NDA”)
submission. The proposed NDA package will also include Entera’s scientific bridge analysis with Forteo® (teriparatide SC injection,
Eli Lilly) under the 505(b)(2) pathway, and a transiliac crest bone biopsy sub-study in a subset of patients. The FDA also agreed with
Entera’s proposal to continue following randomized patients for 24 months in an open-label extension study under a separate protocol.
Entera plans to submit data through up to 18 months as part of the 120-day safety update to its NDA. Additionally, Entera will submit
the complete 2-year data upon completion of the open-label extension study to characterize further the durability of the treatment effect,
safety, and sequence data for EB613 followed by a standard anti-resorptive therapy for 12 months. Entera plans to initiate the registrational
Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.
· Single Tablet EB613 Data Presented as Late-Breaking
Oral at ENDO 2026: In June 2026, at the annual meeting of the Endocrine Society (ENDO 2026), Entera presented comparative Phase 1
data demonstrating that single-tablet EB613 achieved a pharmacokinetic (PK) and pharmacodynamic (PD) profile comparable to both multi-tablet
EB613, which was evaluated in the Company’s Phase 2 study, and Forteo®. Comparable calcemic effects and consistent suppression
of endogenous PTH(1-84) were shown for both oral EB613 treatments and Forteo®. These data support advancing single-tablet EB613 into
the planned Phase 3 registrational study.
· Key Opinion Leader (KOL) Webinar on Osteoporosis
Treatment Landscape: On April 20, 2026, Entera hosted a virtual KOL roundtable with Dr. Felicia Cosman (Professor of Medicine at Columbia
University and a globally recognized authority in osteoporosis and anabolic therapies) and Dr. Steven Goldstein (Professor of Obstetrics
and Gynecology at New York University Grossman School of Medicine and former President of both the International Menopause Society and
the North American Menopause Society) to gain endocrinology and gynecology insights into the current osteoporosis treatment paradigm.
The KOLs highlighted the critical unmet demand for an oral anabolic in this silent, asymptomatic disease and EB613’s potential to
transform the treatment paradigm. The full transcript is available here.
· EB613 Data Selected for Plenary Poster Presentation
at ASBMR 2026: In August 2026, Entera announced that new Phase 2 analysis of EB613 in postmenopausal women with osteoporosis at high
risk of fracture was selected for a plenary poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual
Meeting, taking place October 9–12, 2026 in Boston, Massachusetts.
EB612: First-in-Class Oral Long-Acting PTH(1-34)
Replacement Tablet for Hypoparathyroidism
· Robust Preclinical Data Presented at ENDO
2026: In June 2026, Entera reported preclinical data for EB612, a proprietary first-in-class long-acting PTH(1-34) analog formulated
with Entera’s N-Tab® oral peptide platform, at ENDO 2026. Across three preclinical models - a thyroparathyroidectomized (TPTx)
rat model, a minipig model, and a non-human primate model - single oral doses of EB612 produced robust bioavailability and rapid, sustained
increases in serum calcium lasting approximately three days. EB612 was well tolerated with no safety concerns identified, and the calcemic
effects were consistent with those reported for clinically validated injectable PTH-replacement therapies for hypoparathyroidism. Following
the previously announced expansion of the Company’s collaboration with OPKO Health (“OPKO”) in February 2026, Entera
and OPKO intend to file an Investigational New Drug (IND) application for EB612 in the first half of 2027.
EB618: First-in-Class Oral Dual GLP-1/Glucagon
(Oxyntomodulin) Tablet for Obesity and Metabolic Disorders
· Non-Human Primate PK/PD Data Presented at
ENDO 2026: In June 2026, Entera reported single-dose PK/PD results in non-human primates for EB618, a proprietary long-acting oxyntomodulin
analog formulated with Entera’s N-Tab® platform, at ENDO 2026. EB618 exhibited robust bioavailability with dose-proportional
systemic exposure across three tested tablet strengths and low variability and produced a dose-proportional pharmacologic effect on postprandial
blood glucose levels. EB618 was well tolerated at doses exceeding the anticipated clinical dose range by more than tenfold. These data
support the continued clinical development of EB618 as a potential first-in-class oral once-daily GLP-1/glucagon receptor agonist for
the treatment of obesity and metabolic disorders. As previously disclosed, Entera expects to evaluate the initiation of EB618 clinical
development pursuant to analysis of the Phase 1 SAD/MAD studies of subcutaneous injectable OXM being conducted by OPKO.
Corporate Highlights
· Oversubscribed $275 Million Private Placement:
Subsequent to quarter end, in July 2026, Entera announced the oversubscribed private placement which provided gross proceeds of approximately
$275.0 million before deducting placement agent fees and offering expenses. The Private Placement was led by existing investor BVF, with
participation from new investors, including Longitude Capital, Vivo Capital, TCGX, Spruce Street Capital, Venrock Healthcare Capital Partners,
RA Capital Management, Perceptive Advisors, Driehaus Capital Management, Logos Capital, and Catalio Capital Management, among others.
Upon closing of the Private Placement, BVF was granted the right to designate two directors to the Company’s board of directors.
The net proceeds are anticipated to fully support the Phase 3 registrational program of EB613 through the anticipated submission of NDA
to the FDA, advance EB612 into the clinic in collaboration with OPKO and extend the Company’s cash runway into 2030.
· Direct Investment Led by BVF: In April
2026, Entera announced a private placement led by BVF for approximately $10.0 million in gross proceeds, with the potential for up to
$24.5 million in total proceeds upon full exercise of accompanying five-year warrants.
Financial Results for the Three Months Ended
June 30, 2026
Cash and cash equivalents were $11.3 million
as of June 30, 2026, and restricted cash was $7.1 million, primarily designated to fund the OPKO collaboration. On a pro forma basis,
following the closing of the July 2026 private placement in which the Company received aggregate gross proceeds of approximately $275.0
million, the Company’s cash resources are expected to be sufficient to fully fund the planned Phase 3 registrational program of
EB613 through topline results and the anticipated submission of an NDA to the FDA and to support the Company’s operations into 2030.
Research and development expenses for the
three months ended June 30, 2026 were $3.2 million, as compared to $1.5 million for the three months ended June 30, 2025. The increase
of $1.7 million was primarily attributable to increased materials, production and other costs related to the preparation of the EB613
Phase 3 program and to activities under the OPKO collaboration.
General and administrative expenses for
the three months ended June 30, 2026 were $1.4 million, as compared to $1.1 million for the three months ended June 30, 2025.
Net loss was $7.3 million, or $0.14 per
ordinary share (basic and diluted), for the three months ended June 30, 2026, as compared to $2.7 million, or $0.06 per ordinary share
(basic and diluted), for the three months ended June 30, 2025. The increase was primarily driven by a $2.7 million non-cash fair value
remeasurement of the pre-funded warrants issued in our April 2026 private placement, which are classified as a financial liability.
About Entera
Entera is a clinical stage company focused on
developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential
to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline
of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed
as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study
of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first
oral Long-Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin,
a dual targeted GLP-1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as
an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration
with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter,
and Facebook.
Cautionary Statement Regarding Forward Looking
Statements
Various statements in this press release are “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of
historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities,
collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited
to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,”
“design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,”
“predict,” “project,” “target,” “likely,” “should,” “will,” and
“would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking
statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking
statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance
or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s
forward-looking statements include, among others: the anticipated use of proceeds from the July 2026 private placement; the timing, design,
and results of the planned Phase 3 registrational study of EB613; the FDA’s ongoing review of the EB613 program, including the terms
and interpretation of the FDA’s feedback on our Clinical Amendment; the timing of the anticipated IND filings for EB612 and EB618
in collaboration with OPKO Health; the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals
for our product candidates; changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation
and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development
and clinical trials; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing
Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to
establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with
limited operating history; Entera’s competitive position with respect to other products on the market or in development for the
treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues;
Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain
regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards
and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual
property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary
Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the
SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance
that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have
the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such
forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera
makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes
no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise,
except to the extent required by law.
Company Contact:
IR@enterabio.com
ENTERA BIO LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands)
June 30,
December 31,
2026
2025
(Unaudited)
(Audited)
Cash and cash equivalents
11,309
7,108
Restricted cash
7,122
7,775
Accounts receivable and other current assets
465
415
Property and equipment, net
121
134
Other assets
463
561
Total assets
19,480
15,993
Accounts payable and other current liabilities
2,104
2,203
Pre-funded warrants liability
9,563
—
Other non-current liabilities
547
689
Total liabilities
12,214
2,892
Total shareholders’ equity
7,266
13,101
Total liabilities and shareholders’ equity
19,480
15,993
ENTERA BIO LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and
per share data)
(Unaudited)
Three Months Ended
June 30,
2026
2025
REVENUES
—
—
COST OF REVENUES
—
—
GROSS PROFIT
—
—
OPERATING EXPENSES:
Research and development
3,201
1,520
General and administrative
1,362
1,148
TOTAL OPERATING EXPENSES
4,563
2,668
OPERATING LOSS
4,563
2,668
FINANCIAL EXPENSES (INCOME), NET
2,749
(12 )
NET LOSS
7,312
2,656
LOSS PER SHARE BASIC AND DILUTED
0.14
0.06
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE
50,451,232
46,836,700
GRAPHIC
GRAPHIC
Filename: image_001.jpg · Sequence: 6
Binary file (2747 bytes)
Download image_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Cover
May 08, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 07, 2026
Entity File Number
001-38556
Entity Registrant Name
Entera Bio Ltd.
Entity Central Index Key
0001638097
Entity Tax Identification Number
00-0000000
Entity Incorporation, State or Country Code
L3
Entity Address, Address Line One
Kiryat Hadassah, Minrav Building
Entity Address, Address Line Two
Fifth
Floor
Entity Address, City or Town
Jerusalem
Entity Address, Country
IL
Entity Address, Postal Zip Code
9112002
City Area Code
972
Local Phone Number
2-532-7151
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Ordinary Shares, par value of NIS 0.0000769
Trading Symbol
ENTX
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration